The tb diagnostic segmentation by application delineates four primary uses that together drive the market’s revenue stream. Clinical diagnosis accounts for the largest share, roughly 45 % of total sales, because point‑of‑care and laboratory‑based tests are required for confirming active disease in symptomatic patients. Drug‑susceptibility testing (DST) follows with an estimated 30 % contribution, reflecting the growing need for rapid resistance profiling as multidrug‑resistant TB prevalence rises worldwide. Screening and surveillance represents about 15 % of the market, encompassing community‑level programs, occupational health checks, and contact‑tracing initiatives that rely on high‑throughput, cost‑effective assays. The remaining 10 % is allocated to research and development activities, where specialized kits and platforms support epidemiological studies, biomarker discovery, and validation of novel diagnostics. Each application segment influences the overall market size by dictating product mix, pricing dynamics, and investment priorities, making the application‑level taxonomy essential for strategic planning. Consequently, manufacturers tailor portfolios to align with reimbursement frameworks and regional health‑policy mandates, reinforcing the link between application focus and revenue growth.
